Mediclinic International plc Director/PDMR Shareholding (4923X)
10 August 2018 - 11:00PM
UK Regulatory
TIDMMDC
RNS Number : 4923X
Mediclinic International plc
10 August 2018
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
10 August 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 8 August 2018, Mr Jurgens Myburgh, Chief Financial Officer of
Mediclinic International plc, acquired 20,000 shares in the Company
at ZAR 86.82 per share. Accordingly, Mr Myburgh now owns a total of
80,000 shares in Mediclinic International plc.
The following notification is made in accordance with Articles
19.1 and 19.3 of the Market Abuse Regulation.
1. Details of PDMR / persons closely associated with them
("PCA")
a) Name Mr Petrus Jurgens Myburgh
------------------------- ----------------------------------------
2. Reason for the notification
-------------------------------------------------------------------
a) Position / status Chief Financial Officer of the Company
------------------------- ----------------------------------------
b) Initial notification Initial Notification
/ amendment
------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Mediclinic International plc
------------------------- ----------------------------------------
b) LEI 2138002S5BSBIZTD5I60
------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
------------------------- ----------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------- ----------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ZAR 86.82 per share 20 000
----------
------------------------- ----------------------------------------
d) Aggregated information
Aggregated volume
Price
20 000
ZAR 86.82
------------------------- ----------------------------------------
e) Date of the 8 August 2018; 14:21 UTC
transaction
------------------------- ----------------------------------------
f) Place of the Johannesburg Stock Exchange
transaction
------------------------- ----------------------------------------
About Mediclinic International plc
Mediclinic is an international private healthcare services group
with operating divisions in Switzerland, Southern Africa (South
Africa and Namibia) and the United Arab Emirates. Its core purpose
is to enhance the quality of life of patients by providing acute
care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire
Healthcare Group plc, an LSE-listed and UK-based private healthcare
group.
Mediclinic comprises 74 hospitals and 30 clinics. Hirslanden
operates 17 private acute care facilities and 4 clinics in
Switzerland with more than 1 800 inpatient beds; Mediclinic
Southern Africa operates 48 hospitals and 2 day clinics throughout
South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6
hospitals and 24 clinics with more than 700 inpatient beds in the
United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE
in the United Kingdom, with secondary listings on the JSE in South
Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International
plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBGGDIGSBBGIG
(END) Dow Jones Newswires
August 10, 2018 09:00 ET (13:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024